LONDON--(BUSINESS WIRE)--
03 June 2016
ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.
This approval will allow ECO to start selling Aivlosin® for the medication of drinking water for the treatment of respiratory infection caused by Mycoplasma gallisepticum in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.
Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Peter Lawrence, Chairman of ECO, commented “This approval from the European regulatory authorities is an important step in the development of Aivlosin® for commercial layers. ECO is now able to accelerate the submission of the Aivlosin® regulatory files for the treatment of layers in the key global egg producing markets. It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.”
Contacts:
ECO Animal Health Group plc Peter Lawrence 020 8336 6190
Marc Loomes 020 8447 8899
Spiro Financial Anthony Spiro 020 8336 6196
Peel Hunt LLP Dan Webster 020 7418 8900
(Nominated Adviser) Adrian Trimmings 020 7418 8900
George Sellar 020 7418 8900
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.